Acecainide. Acecainide Hydrochloride . Acecainide Monohydrochloride . N-Acetylprocainamide . Hydrochloride, Acecainide . Monohydrochloride, Acecainide . N Acetylprocainamide . Acetylprocainamide . A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure. . 1.00
Renal Insufficiency. Kidney Failure . Renal Failure . Failure, Kidney . Failure, Renal . Failures, Kidney . Failures, Renal . Insufficiency, Kidney . Kidney Failures . Kidney Insufficiencies . Renal Failures . Renal Insufficiencies . Kidney Insufficiency . Renal Failure . Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE. . 0.45
Anti-Arrhythmia Agents. Anti-Arrhythmia Drugs . Anti-Arrhythmics . Antiarrhythmia Agents . Antiarrhythmia Drugs . Antiarrhythmic Drugs . Agents, Anti-Arrhythmia . Agents, Antiarrhythmia . Agents, Antifibrillatory . Anti Arrhythmia Agents . Anti Arrhythmia Drugs . Anti Arrhythmics . Depressants, Cardiac . Depressants, Myocardial . Drugs, Anti-Arrhythmia . Drugs, Antiarrhythmia . Drugs, Antiarrhythmic . Antifibrillatory Agents . Cardiac Depressants . Myocardial Depressants . Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. . 0.42